Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Study the differential gene expression of HEPA1-6 tumors in C57/BL6 Mouse tumors treated with vehicle or EZH2 inhibitor GSK343

ABSTRACT: The study evaluated the differential gene expression in mice tumors treated with or without GSK343, which were then analyzed by RNA-seq for identify differentially regulated genes.

ORGANISM(S): Mus musculus

PROVIDER: GSE166553 | GEO | 2021/07/10

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Study the differential gene expression of C57/BL6 Mouse tumors treated with EZH2 inhibitor GSK343 II

Project description:The study evaluated the differential gene expression in control Antibody or Ant-CXCL10 antibody injected mouse when compared to EZH2 inhibitor GSK343 treated mice tumors Briefly, control Antibody or Ant-CXCL10 antibody injected C57BL/6 mouse were treated with or without GSK343were analyzed for RNA-seq

2021-10-25 | GSE160176 | GEO

Study the differential gene expression of HEPA1-6 tumors in C57/BL6 Mouse tumors treated with vehicle or EZH2 inhibitor GSK343

Project description:Study the differential gene expression of HEPA1-6 tumors in C57/BL6 Mouse tumors treated with vehicle or EZH2 inhibitor GSK343

| PRJNA701266 | ENA

Study the differential gene expression of C57/BL6 Mouse tumors treated with EZH2 inhibitor GSK343 II

Project description:Study the differential gene expression of C57/BL6 Mouse tumors treated with EZH2 inhibitor GSK343 II

| PRJNA672164 | ENA

Treatment of CML CD34+ cells with EZH2 inhibitor GSK343

Project description:Transcriptional profiling by array of CML CD34+ cells to understand the response of chronic myeloid leukaemia stem cells to an EZH2 inhibitor, GSK343.

2016-11-01 | E-MTAB-2893 | biostudies-arrayexpress

Treatment of non-CML CD34+ cells with EZH2 inhibitor GSK343

Project description:Transcriptional profiling of non-CML CD34+ cells to understand the response of non-CML stem cells to an EZH2 inhibitor, GSK343.

2016-11-01 | E-MTAB-3552 | biostudies-arrayexpress

Study the differential gene expression in A375 cells treated with DMSO or XL413 or GSK343 or GSK343 and XL413 combination

Project description:The study evaluated the differential gene expression in A375 cells treated with DMSO when compared to XL413 or GSK343 or GSK343 and XL413 combination using RNA-seq

2022-08-10 | GSE186276 | GEO

Inhibition of histone methyltransferase EZH2 in Schistosoma mansoni by GSK343 decreases the expression of genes implicated in DNA replication and ncRNA metabolism

Project description:Schistosomiasis is a chronic and debilitating disease caused by a trematode of the genus Schistosoma. The current strategy for the control of the disease involves treatment with Praziquantel, the only available drug. The development of new drugs is therefore a top priority. Drugs that inhibit histone modifying enzymes have been used in cancer, altering gene expression, replication, repair and DNA recombination. Schistosoma parasites have some characteristics similar to malignant tumors, such as intense cell division and high levels of metabolic activity. Here we evaluate in Schistosoma mansoni the effect of GSK343, an inhibitor of the histone methyltransferase EZH2 that had been shown to arrest or reduce the growth of human cancer cells. We show that GSK343 causes damage to the parasite tegument and reduces egg laying in vitro, concomitant with a decrease in levels of H3K27me3, the histone mark put in place by EZH2. RNA-seq and proteomic analyses of treated parasites showed changes in the expression of hundreds of genes involved in important metabolic processes. In females, a marked decrease was observed in the expression of genes related to processes such as DNA replication and noncoding RNA metabolism. In conclusion, the histone methyltransferase EZH2 seems to be a promising novel drug target against schistosomiasis.

2018-11-23 | PXD010342 | Pride

The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells.

Project description:Enhancer of zeste homolog 2 (EZH2) is the catalytic unit of polycomb repressive complex 2 (PRC2) which epigenetically silences many genes involved in tumor-suppressive mechanisms via the trimethylation of lysine 27 of histone H3 (H3K27me3). We recently found that overexpression of EZH2 was associated with poor outcome of glioblastoma (GBM). In this study, we examined the antitumor effects of the EZH2 inhibitor GSK343 on glioma cells in vitro and in vivo. The proliferation and cell cycle of glioma cells was measured. Wound healing assay and transwell invasion assay were performed to evaluate the capacity of migration and invasion of glioma cells. Western blot, qPCR, immunoprecipitation and fluorescent staining were used to test the levels of EZH2 and associated proteins. Spheroid formation assay and clonogenic assays were conducted to assess the stemness of glioma stem cells. Finally, the effect of GSK343 was measured through a nude mice model with intracranially xenotransplanted glioma. We found that GSK343 reduced proliferation, attenuated cell motility and reversed epithelial-mesenchymal transition in U87 and LN229 glioma cells. GSK343 also suppressed the stemness of cell lines and patient derived glioma stem cells. Further, GSK343 inhibited histone H3K27 methylation and upregulated the expression of EZH2 target genes thereby regulating the levels of markers involved in epithelial-mesenchymal transition and stemness. Taken together, our results indicate that GSK343 could be a potential drug against glioblastoma.

| S-EPMC5716734 | biostudies-literature

Characterizing transcriptional consequences of EZH2 inhibitor withdrawal for Karpas-422 CXCdel cells

Project description:We characterized the effects that the the withdrawal of the EZH2 inhibitor, GSK343, has on Karpas-422 CXCdel cells

2023-02-08 | GSE199811 | GEO

Genes regulated by GSK343 in HepG2 and A549 cells

Project description:Our previous study has found that GSK343 is a potent autophagy inducer. To further investigate the underlying mechanisms, microarray analysis was performed.

2019-04-03 | GSE129201 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data